Trevi Therapeutics (TRVI)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Trevi Therapeutics (TRVI)
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Key Insights
Critical company metrics and information
Share Price
$2.60Market Cap
$199.85 MillionTotal Outstanding Shares
76.87 Million SharesTotal Employees
27Dividend
No dividendIPO Date
May 3, 2019SIC Description
Pharmaceutical PreparationsHomepage
https://www.trevitherapeutics.com
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $-9.56 Million |
| Net Cash Flow From Financing Activities | $4.98 Million |
| Net Cash Flow From Investing Activities | $7.67 Million |
| Net Cash Flow From Investing Activities, Continuing | $7.67 Million |
| Net Cash Flow From Operating Activities | $-9.56 Million |
| Net Cash Flow From Financing Activities, Continuing | $4.98 Million |
| Net Cash Flow | $3.09 Million |
| Net Cash Flow, Continuing | $3.09 Million |
Income Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Revenues | $0.00 |
| Nonoperating Income/Loss | $814000.00 |
| Income/Loss From Continuing Operations After Tax | $-13.24 Million |
| Other Operating Expenses | $2.86 Million |
| Research and Development | $11.22 Million |
| Diluted Earnings Per Share | $0.13 |
| Income/Loss From Continuing Operations Before Tax | $-13.27 Million |
| Net Income/Loss Attributable To Parent | $-13.24 Million |
| Diluted Average Shares | $101.28 Million |
| Basic Earnings Per Share | $0.13 |
| Basic Average Shares | $101.28 Million |
| Net Income/Loss | $-13.24 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-13.24 Million |
| Income Tax Expense/Benefit | $31000.00 |
| Operating Expenses | $14.09 Million |
| Operating Income/Loss | $-14.09 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Balance Sheet
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Prepaid Expenses | $1.18 Million |
| Liabilities And Equity | $68.91 Million |
| Equity Attributable To Parent | $58.97 Million |
| Noncurrent Liabilities | $816000.00 |
| Assets | $68.91 Million |
| Noncurrent Assets | $1.57 Million |
| Liabilities | $9.94 Million |
| Other Current Liabilities | $7.51 Million |
| Current Assets | $67.34 Million |
| Other Current Assets | $66.16 Million |
| Equity | $58.97 Million |
| Other Non-current Assets | $1.40 Million |
| Accounts Payable | $1.61 Million |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Current Liabilities | $9.12 Million |
| Fixed Assets | $174000.00 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.